JP7816735B2 - 腫瘍溶解性ウイルス及びそれを用いたがん治療 - Google Patents

腫瘍溶解性ウイルス及びそれを用いたがん治療

Info

Publication number
JP7816735B2
JP7816735B2 JP2025546071A JP2025546071A JP7816735B2 JP 7816735 B2 JP7816735 B2 JP 7816735B2 JP 2025546071 A JP2025546071 A JP 2025546071A JP 2025546071 A JP2025546071 A JP 2025546071A JP 7816735 B2 JP7816735 B2 JP 7816735B2
Authority
JP
Japan
Prior art keywords
promoter
nucleic acid
cxcl10
cancer
acid encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025546071A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025159067A5 (https=
JPWO2025159067A1 (https=
Inventor
健一郎 小戝
真季 渡邉
恵理子 松田
侑耶 西川路
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SURV BIOPHARMA INC.
Kagoshima University NUC
Original Assignee
SURV BIOPHARMA INC.
Kagoshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SURV BIOPHARMA INC., Kagoshima University NUC filed Critical SURV BIOPHARMA INC.
Publication of JPWO2025159067A1 publication Critical patent/JPWO2025159067A1/ja
Publication of JPWO2025159067A5 publication Critical patent/JPWO2025159067A5/ja
Application granted granted Critical
Publication of JP7816735B2 publication Critical patent/JP7816735B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2025546071A 2024-01-22 2025-01-21 腫瘍溶解性ウイルス及びそれを用いたがん治療 Active JP7816735B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2024007682 2024-01-22
JP2024007682 2024-01-22
PCT/JP2025/001686 WO2025159067A1 (ja) 2024-01-22 2025-01-21 腫瘍溶解性ウイルス及びそれを用いたがん治療

Publications (3)

Publication Number Publication Date
JPWO2025159067A1 JPWO2025159067A1 (https=) 2025-07-31
JPWO2025159067A5 JPWO2025159067A5 (https=) 2025-12-23
JP7816735B2 true JP7816735B2 (ja) 2026-02-18

Family

ID=96545359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025546071A Active JP7816735B2 (ja) 2024-01-22 2025-01-21 腫瘍溶解性ウイルス及びそれを用いたがん治療

Country Status (3)

Country Link
JP (1) JP7816735B2 (https=)
TW (1) TW202546223A (https=)
WO (1) WO2025159067A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019014696A (ja) 2017-07-10 2019-01-31 株式会社Ｉｄファーマ 癌の治療組成物
WO2019093435A1 (ja) 2017-11-08 2019-05-16 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
WO2021029385A1 (ja) 2019-08-09 2021-02-18 Ｋｍバイオロジクス株式会社 腫瘍溶解性ワクシニアウイルス
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
JP2022536929A (ja) 2019-06-14 2022-08-22 ティルト バイオセラピューティクス オサケユキチュア 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019014696A (ja) 2017-07-10 2019-01-31 株式会社Ｉｄファーマ 癌の治療組成物
WO2019093435A1 (ja) 2017-11-08 2019-05-16 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
JP2022536929A (ja) 2019-06-14 2022-08-22 ティルト バイオセラピューティクス オサケユキチュア 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法
WO2021029385A1 (ja) 2019-08-09 2021-02-18 Ｋｍバイオロジクス株式会社 腫瘍溶解性ワクシニアウイルス

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAMDAN, F. et al.，Molecular Therapy: Methods & Clinical Development，2021年，Vol.20，p.625-634
WATANABE, M. et al.，Viruses，2021年，Vol.13, Article No. 2502，pp.1-15

Also Published As

Publication number Publication date
TW202546223A (zh) 2025-12-01
WO2025159067A1 (ja) 2025-07-31
JPWO2025159067A1 (https=) 2025-07-31

Similar Documents

Publication Publication Date Title
KR102626276B1 (ko) 이-특이적인 항체를 암호화하는 종양붕괴성 아데노바이러스 및 이와 관련된 방법 및 용도
JP6375273B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
McCart et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes
CN109576231B (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US11850215B2 (en) Recombinant adenoviruses and stem cells comprising same
CN1526012A (zh) 一种高效表达抗癌基因的肿瘤细胞内特异性增殖的病毒及其用途
JP6238485B2 (ja) Ａｕｒｏｒａキナーゼプロモーターを含む増殖制御型ウイルスベクター
JP2006502726A (ja) 改善された免疫療法
JP7816735B2 (ja) 腫瘍溶解性ウイルス及びそれを用いたがん治療
US7371570B2 (en) Cell-specific adenovirus vector comprising EBV-specific promoter
US20240165175A1 (en) Muc16 promoter containing virus
EP4048798B1 (en) Adenovirus comprising a modified adenovirus hexon protein
WO2011118819A1 (ja) サービビンプロモーターを含む増殖制御型ウイルスベクターによる造血器腫瘍の遺伝子治療
US20060275262A1 (en) Conditionally replicating viruses and methods for cancer virotherapy
CA3156880A1 (en) Replication-enhanced oncolytic adenoviruses
RU2678003C1 (ru) Рекомбинантный онколитический штамм вируса осповакцины Л-ИВП_oncoQ, содержащий гены, кодирующие гранулоцитарно-макрофагальный колониестимулирующий фактор и полиэпитопный иммуноген, состоящий из эпитопов антигенов, гиперэкспрессирующихся опухолевыми клетками при раке яичников
RU2678060C1 (ru) Рекомбинантный онколитический штамм вируса осповакцины Л-ИВП_oncoM, содержащий гены, кодирующие гранулоцитарно-макрофагальный колониестимулирующий фактор и полиэпитопный иммуноген, состоящий из эпитопов антигенов, гиперэкспрессирующихся опухолевыми клетками при меланоме
CN101538556B (zh) 腺病毒选择性互补复制的方法
EP1948792A1 (en) Conditionally replicating viruses and methods for cancer virotherapy
HK40003250B (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
CN113774031A (zh) 一种复制型人腺病毒及其应用
Kinase Systemic Cancer Therapy with a Tumor-selective Vaccinia
HK40003250A (en) Isolated recombinant oncolytic adenovirus, pharmaceutical composition, and application of isolated recombinant oncolytic adenovirus in medication for treatment of tumor and/or cancer
TW200533752A (en) Pan cancer oncolytic vectors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250806

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250806

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260128

R150 Certificate of patent or registration of utility model

Ref document number: 7816735

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150